Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.

Due to the small patient number in the KMT2C ‐MUT subgroup, the study only showed a trend toward a higher rate of DCB relative to the KMT2C ‐WT subgroup (48% vs. 28%, respectively; p = 0.07) (Figure 2J ).

also in 53,322 other papers